Compare Cytokinetics Inc (CYTK) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs HCA Health Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while HCA Health Inc trades at $443.69 (market cap $95.08B). The key difference: HCA Health Inc is far larger — about 11.2× Cytokinetics Inc's market cap, and HCA Health Inc pays a 0.71% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and HCA Health Inc for 76 Days on average.
| CYTK | HCA | |
|---|---|---|
Market Cap | $8.50B | $95.08B |
Volume | 2,395,556 | 998,787 |
Sector | Health | Health |
52-Week High | $87.26 | $545.13 |
52-Week Low | $54.76 | $361.32 |
Typical Hold Time | 19 Days | 76 Days |
Enterprise Value | $8.60B | $145.62B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
HCA Healthcare (HCA) trades at $445.01, up 2.96% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.6B in 2025, with net income of $6.78B, and the stock trades at a P/E of 14.73. Analyst consensus is a Buy with a $461.12 price target, though ongoing legal investigations pose a headwind.
The outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and high debt levels. Upside potential exists if earnings growth continues, but investors should monitor legal developments and interest rate impacts on the leveraged balance sheet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
